deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT00494182

Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

A Phase II Study of Sorafenib in Combination With Carboplatin and Paclitaxel in Metastatic or Recurrent Head and Neck Squamous Cell Cancer

Sponsor: M.D. Anderson Cancer Center

Conditions Metastatic Head and Neck Squamous Cell Carcinoma Metastatic Squamous Cell Carcinoma of the Hypopharynx Metastatic Squamous Cell Carcinoma of the Larynx Metastatic Squamous Cell Carcinoma of the Oral Cavity Metastatic Squamous Cell Carcinoma of the Oropharynx Recurrent Head and Neck Squamous Cell Carcinoma Recurrent Hypopharyngeal Squamous Cell Carcinoma Recurrent Laryngeal Squamous Cell Carcinoma Recurrent Oral Cavity Squamous Cell Carcinoma Recurrent Oropharyngeal Squamous Cell Carcinoma
Interventions Carboplatin Paclitaxel Sorafenib
Updated 18 times since 2017 Last updated: Dec 11, 2025 Started: Apr 25, 2007 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Metastatic Head and Neck Squamous Cell Carcinoma and Metastatic Squamous Cell Carcinoma of the Hypopharynx, this trial is ongoing. The trial is conducted by M.D. Anderson Cancer Center and has accumulated 18 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshot~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Jul 2019 · 9 months · monthly snapshot~Jul 2019 – ~Jan 2021 · 18 months · monthly snapshot~Jan 2021 – ~May 2022 · 16 months · monthly snapshot~May 2022 – ~Mar 2023 · 10 months · monthly snapshot~Mar 2023 – ~Sep 2023 · 6 months · monthly snapshot~Sep 2023 – ~Jun 2024 · 9 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – ~Jun 2025 · 5 months · monthly snapshot~Jun 2025 – ~Dec 2025 · 6 months · monthly snapshot~Dec 2025 – ~Jan 2026 · 31 days · monthly snapshot~Jan 2026 – present · 6 months · monthly snapshot

Change History

18 versions recorded

  1. Jan 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Dec 2025 — Jan 2026 [monthly]

    Active Not Recruiting PHASE2

  3. Jun 2025 — Dec 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Jan 2025 — Jun 2025 [monthly]

    Active Not Recruiting PHASE2

  5. Sep 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE2

▶ Show 13 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2023 — Jun 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Mar 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE2

  5. May 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE2

  6. Jan 2021 — May 2022 [monthly]

    Active Not Recruiting PHASE2

  7. Jul 2019 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  8. Oct 2018 — Jul 2019 [monthly]

    Active Not Recruiting PHASE2

  9. Sep 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE2

  10. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE2

  11. Sep 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  12. Feb 2017 — Sep 2017 [monthly]

    Active Not Recruiting PHASE2

  13. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Apr 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
  • National Cancer Institute (NCI)
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations